Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

529.24
+7.401.42%
Post-market: 528.02-1.2200-0.23%19:58 EDT
Volume:951.91K
Turnover:499.83M
Market Cap:57.16B
PE:13.42
High:529.55
Open:518.25
Low:514.98
Close:521.84
Loading ...

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Yesterday

Press Release: 23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

Dow Jones
·
Yesterday

BRIEF-23Andme Reaches Agreement For Sale Of Business To TTAM Research Institute

Reuters
·
Yesterday

23andMe's founder Anne Wojcicki wins bid for DNA testing firm

Reuters
·
Yesterday

23andMe Reaches Agreement for Sale of Business to Ttam Research Institute Following Final Round of Bidding in Court-Approved Sale Process

THOMSON REUTERS
·
Yesterday

23andMe Holding Co - Deal Subject to U.S. Bankruptcy Court Approval

THOMSON REUTERS
·
Yesterday

23andMe Holding Co - to Sell Assets to Ttam for $305 Mln

THOMSON REUTERS
·
Yesterday

Citi Remains a Buy on Regeneron (REGN)

TIPRANKS
·
10 Jun

Regeneron Pharmaceuticals Inc. Stock Advances 4.9%, Outperforms Competitors

Dow Jones
·
10 Jun

Regeneron Exec Says Says Tariff Situation Currently Enacted Is Not "Material" to Business, but Sectoral Tariffs Could Have an Impact

THOMSON REUTERS
·
09 Jun

Regeneron Exec Says Says 23andMe Auction Process Was Recently Reopened and Is "Fairly Complicated" - Goldman Sachs Conference

THOMSON REUTERS
·
09 Jun

JPMorgan cuts Regeneron target, says selloff ‘very much overdone’

TIPRANKS
·
09 Jun

JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $800 From $950, Maintains Overweight Rating

MT Newswires Live
·
09 Jun

Regeneron, Sanofi Say Atopic Dermatitis Trial Shows Improvement in Disease Severity

MT Newswires Live
·
09 Jun

U.S. RESEARCH ROUNDUP-Intuitive Surgical, Oracle, Regeneron Pharmaceuticals

Reuters
·
09 Jun

Regeneron, Sanofi presents results from DISCOVER Phase 4 trial of Dupixent

TIPRANKS
·
08 Jun

Regeneron Pharmaceuticals Announces Positive Results from Dupixent Trial in Atopic Dermatitis Patients with Skin of Color at RAD Conference

Reuters
·
08 Jun

Dupixent® (Dupilumab) Data at Revolutionizing Atopic Dermatitis (Rad) Conference Reinforce Use in Atopic Dermatitis Patients With Skin of Color

THOMSON REUTERS
·
08 Jun

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
07 Jun

Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial -- Barrons.com

Dow Jones
·
06 Jun